Osteoporosis medication dispensing for older Australian women from 2002 to 2010: Influences of publications, guidelines, marketing activities and policy

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 12, 2014, Pages 1303-1311

  Peeters, Geeske ^a   Tett, Susan E ^a   Duncan, Emma L ^a,b   Mishra, Gita D ^a   Dobson, Annette J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Guidelines; Medication use; Osteoporosis; Pharmacoepidemiology; Women

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

AGED; AUSTRALIA; CLINICAL PRACTICE; DRUG UTILIZATION; FEMALE; HISTORY; HUMAN; LONGITUDINAL STUDY; MARKETING; OSTEOPOROSIS; PUBLICATION; STATISTICS AND NUMERICAL DATA; TRENDS;

AGED; AUSTRALIA; BONE DENSITY CONSERVATION AGENTS; DRUG UTILIZATION; FEMALE; HISTORY, 21ST CENTURY; HUMANS; LONGITUDINAL STUDIES; MARKETING; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; PUBLICATIONS;

EID: 84913597924     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3703     Document Type: Article

References (33)

1. Teixeira Rodrigues A, Roque F, Falcao A, Figueiras A, Herdeiro MT. Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. Int J Antimicrob Agents 2012; 41(3): 203-212. doi:10.1016/j.ijantimicag.2012.09.003.
2. Sambrook PH, Jiang SC, Simpson JM, March LM. Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 2010; 193: 154-156.
3. Anderson BL, Silverman GK, Loewenstein GF, Zinberg S, Schulkin J. Factors associated with physicians' reliance on pharmaceutical sales representatives. Acad Med 2009; 84(8): 994-1002. doi:10.1097/ACM.0b013e3181ace53a.
4. Pharmaceutical Benefits Scheme, 2011. Available at: http://www.pbs.gov.au/pbs/home [October 2011].
5. Lee C, Dobson AJ, Brown WJ, et al. Cohort Profile: the Australian Longitudinal Study on Women's Health. Int J Epidemiol 2005; 34(5): 987-991. doi:10.1093/ije/dyi098.
6. Therapeutic Guidelines Limited. Therapeutic Guidelines: improving health outcomes through authoritative, practical, independent therapeutic guidance, 2011. Available at: http://www.tg.org.au/index.php?sectionid=1 [12 September 2012]
7. Therapeutic Goods Administration Therapeutic Goods Administration - Australia's regulartory authority for therapeutic goods. Available at: http://www.tga.gov.au/index.htm [12 September 2012]
8. National Prescribing Service National Prescribing Service. Available at: http://www.nps.org.au/ [12 September 2012]
9. The Royal Australian College of General Practitioners. Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men, South Melbourne, Australia, 2010.
10. Australian Broadcasting Corporation. Concern over osteoporosis drug, 2007. Available at: http://www.abc.net.au/7.30/content/2007/s2115904.htm [12 September 2012]
11. Goldberg D, Bridges K, Duncan-Jones P, Grayson D. Detecting anxiety and depression in general medical settings. BMJ 1988; 297(6653): 897-899.
12. World Health Organization. Guidelines for ATC Classification and DDD Assignment (7th edn). WHO Collaborating Centre for Drug Statistics Methodology: Oslo, 2004.
13. O'Neill S, Sambrook P, Diamond T, et al. Guidelines for the treatment of postmenopausal osteoporosis for general practitioners. Aust Fam Physician 2002; 31(10): 921-928.
14. Australian Insitute of Health and Welfare. Australia's Health 2010. AIHW: Canberra, 2010.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-333.
16. O'Neill S, MacLennan A, Bass S, et al. Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 2004; 33(11): 910-919.
17. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29(8): 1548-1558. doi:10.1016/j.clinthera.2007.08.008.
18. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927-2938. doi:10.1001/jama.296.24.2927.
19. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527-534.
20. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. New Engl J Med 2005; 353(1): 99-102; discussion 199-102.
21. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006; 116(1): 115-120. doi:10.1097/01.mlg.0000187398.51857.3c.
22. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479-1491. doi:10.1359/jbmr.0707onj.
23. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77(3): 262-270. doi:10.4065/77.3.262.
24. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148(3): 197-213.
25. Ewald DP, Eisman JA, Ewald BD, et al. Population rates of bone densitometry use in Australia, 2001-2005, by sex and rural versus urban location. Med J Aust 2009; 190(3): 126-128. ewa10511_fm [pii].
26. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. New Engl J Med 1995; 333(22): 1437-1443. doi:10.1056/nejm199511303332201.
27. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282(14): 1344-1352.
28. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637-645.
29. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001; 344(19): 1434-1441. doi:10.1056/nejm200105103441904.
30. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metabol 2005; 90(5): 2816-2822. doi:10.1210/jc.2004-1774.
31. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 2007; 356(18): 1809-1822. doi:10.1056/NEJMoa067312.
32. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. New Engl J Med 2007; 357(18): 1799-1809. doi:10.1056/NEJMoa074941.
33. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 2009; 361(8): 756-765. doi:10.1056/NEJMoa0809493.